UY30641A1 - Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones - Google Patents

Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones

Info

Publication number
UY30641A1
UY30641A1 UY30641A UY30641A UY30641A1 UY 30641 A1 UY30641 A1 UY 30641A1 UY 30641 A UY30641 A UY 30641A UY 30641 A UY30641 A UY 30641A UY 30641 A1 UY30641 A1 UY 30641A1
Authority
UY
Uruguay
Prior art keywords
pirazol
pharmaceutically acceptable
acceptable salts
pyridins
derivatives
Prior art date
Application number
UY30641A
Other languages
English (en)
Inventor
Huifen Chen
Stephen Douglas Barrett
Kramer James Bernard
Mark Laurence Boys
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30641A1 publication Critical patent/UY30641A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Abstract

La presente invencion proprciona compuestos de formula I, y sus sales farmacéuticamente aceptables, en la que R1, R2,R3, R4, R5, R6, y R7 tienen cualquiera de los valores definidos para ellos en la memoria descriptiva, y sus sales farmacéuticamente aceptables, que son utiles como agentes terapeuticos en el tratamiento de trastornos mediados por TGFB, incluyendo el cáncer y trastornos fibroticos. También se proporcionan composiciones farmacéuticas que comprenden uno o más compuestos de formula I.
UY30641A 2006-10-16 2007-10-12 Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones UY30641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85198206P 2006-10-16 2006-10-16

Publications (1)

Publication Number Publication Date
UY30641A1 true UY30641A1 (es) 2008-05-31

Family

ID=38962671

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30641A UY30641A1 (es) 2006-10-16 2007-10-12 Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones

Country Status (16)

Country Link
US (5) US7964612B2 (es)
EP (2) EP2074128B1 (es)
JP (1) JP5443988B2 (es)
KR (1) KR20090066297A (es)
CN (1) CN101528752A (es)
AR (1) AR063318A1 (es)
AU (1) AU2007311560B2 (es)
CA (1) CA2666603C (es)
CL (1) CL2007002916A1 (es)
ES (2) ES2435430T3 (es)
IL (1) IL197750A0 (es)
MX (1) MX2009003157A (es)
NO (1) NO20091247L (es)
TW (1) TW200825094A (es)
UY (1) UY30641A1 (es)
WO (1) WO2008047198A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090066297A (ko) * 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
PT2382205E (pt) 2008-12-29 2014-07-28 Sanofi Sa Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, sua preparação e sua aplicação terapêutica como activadores de hif
ES2511917T3 (es) * 2008-12-29 2014-10-23 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
PL2448581T3 (pl) 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CN102884068A (zh) * 2010-03-15 2013-01-16 国立大学法人广岛大学 噻吩并吡啶衍生物及其制备方法、以及使用该衍生物的有机半导体器件
JP5743418B2 (ja) * 2010-04-09 2015-07-01 Ｏａｔアグリオ株式会社 新規なピラゾール化合物、その製造方法及び有害生物防除剤
WO2012058483A1 (en) 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
SI2651951T1 (sl) 2010-12-16 2015-01-30 F. Hoffmann-La Roche Ag Tricikliäśne p13k inhibitorske spojine in postopki uporabe
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
ES2569712T3 (es) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
HUE039269T2 (hu) 2011-05-03 2018-12-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2012167261A2 (en) * 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
CN102660253B (zh) * 2012-03-07 2014-05-21 泰山医学院 一种吡唑啉衍生物类Ni2+荧光探针及其应用
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP3010898A1 (en) * 2013-06-20 2016-04-27 Basf Se Process for preparing pyridylpyrazole compounds and derivatives thereof from pyridylhydrazine
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
EP3741397A1 (en) 2015-12-11 2020-11-25 Research Institute at Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
AU2017336803A1 (en) * 2016-09-30 2019-04-18 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
CN116249692A (zh) * 2020-09-28 2023-06-09 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
KR20240006582A (ko) * 2021-05-03 2024-01-15 티로나 바이오, 인코포레이티드 Alk-5 (tgf 베타 r1) 억제제로 폐 질환을 치료하기 위한 방법
WO2023212063A1 (en) * 2022-04-29 2023-11-02 Freeman John J Method and composition for treating lung diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
JP2008511630A (ja) * 2004-08-31 2008-04-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＴＧＦ−βインヒビターとしてのピリミジニルピラゾール
US7511056B2 (en) * 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
KR20090066297A (ko) 2006-10-16 2009-06-23 화이자 프로덕츠 인크. 치료용 피라졸릴 티에노피리딘

Also Published As

Publication number Publication date
CN101528752A (zh) 2009-09-09
JP5443988B2 (ja) 2014-03-19
ES2435430T3 (es) 2013-12-19
AR063318A1 (es) 2009-01-21
NO20091247L (no) 2009-04-23
US20150175624A1 (en) 2015-06-25
IL197750A0 (en) 2009-12-24
EP2074128B1 (en) 2013-08-14
US9938289B2 (en) 2018-04-10
AU2007311560B2 (en) 2011-04-21
KR20090066297A (ko) 2009-06-23
ES2559521T3 (es) 2016-02-12
US9090625B2 (en) 2015-07-28
TW200825094A (en) 2008-06-16
EP2527345A1 (en) 2012-11-28
CL2007002916A1 (es) 2008-04-18
MX2009003157A (es) 2009-04-03
CA2666603C (en) 2013-08-06
US20160200735A1 (en) 2016-07-14
US7964612B2 (en) 2011-06-21
AU2007311560A1 (en) 2008-04-24
US20140031385A1 (en) 2014-01-30
US8455512B2 (en) 2013-06-04
CA2666603A1 (en) 2008-04-24
JP2010506895A (ja) 2010-03-04
US20110224251A1 (en) 2011-09-15
WO2008047198A1 (en) 2008-04-24
US9260450B2 (en) 2016-02-16
EP2074128A1 (en) 2009-07-01
US20080090861A1 (en) 2008-04-17
EP2527345B1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
ECSP099728A (es) Compuestos amino-heterocíclicos
UY32391A (es) Compuestos amino-heterocíclicos
DOP2005000064A (es) Nuevos compuestos
UY30500A1 (es) Compuestos de azabencimidazolilo
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY32138A (es) Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
ECSP088968A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
DOP2002000386A (es) Agentes antibacterianos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170727